Browsing tag:

Sofosbuvir


Sofosbuvir is popular in the pharmaceutical headlines as of late, with more positive news for the patient population with Hepatitis C. An NIH (National Institute of Allergy and Infectious Diseases) study released exciting data which showed the use of Sofosbuvir and Ledipasvir elicited a cure rate in only six weeks’ time for patients with the[…]

Read More

The FDA’s approval of Sofosbuvir in December 2013 paved the way for an exciting new treatment option for patients suffering from Hepatitis C. Known as the brand name Sovaldi, which is marketed by Gilead, Sofosbuvir is a unique nucleotide analog inhibitor that is the first Hepatitis C drug to demonstrate efficacy without the co-administration of[…]

Read More

On December 6th, 2013 the FDA announced the approval of Gilead’s once-a-day pill Sofosbuvir, marketed as Sovaldi. The approval comes shortly after an FDA advisory committee awarded Gilead breakthrough therapy status for the once-a-day pill Sofosbuvir at the end of October 2013 (see previous Sofosbuvir article). The FDA committee also unanimously recommended the approval of[…]

Read More

The end of October 2013 saw a nod from the FDA given to Gilead’s New Drug Application for Sofosbuvir. As a greatly needed treatment for hepatitis C Sofosbuvir has proven to be effectual and tolerable in a number of studies. Sofosbuvir is marketed by Gilead Science, Inc. and is clearly set up for success in[…]

Read More

A report in the Journal of the American Medical Association on August 28, 2013 offered exciting news for patients with Hepatitis C. A phase 2 trial of the drugs Sofosbuvir and Ribavirin revealed that this curing combination gives patients with Hepatitis C a viable treatment that is tolerable and effectively clears the virus.  The study[…]

Read More